Impact of stereotactic body radiation therapy on geriatric assessment and management for older patients with head and neck cancer using G8

Impact of stereotactic body radiation therapy on geriatric assessment and management for older patients with head and neck cancer using G8

Management of head and neck cancers (HNC) in older adults is a common but challenging clinical scenario. We assess the impact of Stereotactic Body Radiation Therapy (SBRT) on survival utilizing the Geriatric-8 (G8) questionnaire. 171 HNC patients, deemed medically unfit for definitive treatment, wer...

Full description

Saved in:
Bibliographic Details
Published in:Journal of geriatric oncology 2021-01, Vol.12 (1), p.122-127
Main Authors: Gogineni, Emile, Rana, Zaker, Wotman, Michael, Karten, Jessie, Riegel, Adam, Marrero, Mihaela, Maduro, Luis, Kamdar, Dev, Frank, Douglas, Paul, Doru, Seetharamu, Nagashree, Ghaly, Maged
Format: Article
Language:eng
Subjects:
Cancer
Elderly
Head neck
Older
Prognosis
Quality of life
SBRT
Screening tool
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Management of head and neck cancers (HNC) in older adults is a common but challenging clinical scenario. We assess the impact of Stereotactic Body Radiation Therapy (SBRT) on survival utilizing the Geriatric-8 (G8) questionnaire. 171 HNC patients, deemed medically unfit for definitive treatment, were treated with SBRT ± systemic therapy. G8 questionnaires were collected at baseline, at 4–6 weeks, and at 2–3 months post-treatment. Patients were stratified according to their baseline G8 score: 14 as ‘fit’. Overall survival (OS) was assessed through univariate Kaplan Meier analysis. Repeated measures ANOVA was used to determine if baseline characteristics affected G8 score changes. Median follow-up was seventeen months. 60% of patients presented with recurrent HNC, 30% with untreated HNC primaries, and 10% with metastatic non-HNC primaries. Median age was 75 years. Median Charlson Comorbidity Index score was 2. 51% of patients were ‘vulnerable’, 37% were ‘intermediate’, and 12% were ‘fit' at baseline, with median survival of 13.2, 24.3, and 41.0 months, respectively (p = .004). Patients who saw a decrease in their follow-up G8 score (n = 69) had significantly lower survival than patients who had stable or increased follow-up G8 scores (n = 102), with median survival of 8.6 vs 36.0 months (p 
ISSN:1879-4068
1879-4076